Aika Iwama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aika Iwama has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Fumiya K. Sano
Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan
4 shared publications - Hidetaka S. Oshima
Department of Biological Sciences, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
4 shared publications - Hiroaki Akasaka
Department of Biological Sciences, Graduate School of Science, The University of Tokyo
4 shared publications - Osamu Nureki
Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan
4 shared publications - Wataru Shihoya
Department of Signal Exploration, The Sakaguchi Laboratory, Keio University School of Medicine, Tokyo, Japan
4 shared publications - Akiko Ogawa
Department of Modomics Biology and Medicine, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai 980-8575, Japan; Department of Modomics Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan
1 shared publication
Latest Publications
- Open Access
Structural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor
Adenosine receptors, expressed across various tissues, play pivotal roles in physiological processes and are implicated in diverse diseases, including neurological disorders and inflammation, highlighting the therapeutic potential of receptor-selective agents. The Adenosine A3 receptor (A 3 R), the last identified adenosine receptor, is also activated by breakdown products of post-transcriptionally modified tRNA and exhibits dual roles in neuron, heart, and immune cells, and is often overexpressed in tumors, making it a target for anticancer therapy. Despite extensive studies on the other adenosine receptors, the structure and activation mechanism of A 3 R, especially by selective agonists like N 6 -methyladenosine (m 6 A) and namodenoson, remained elusive. Here, we identified N 6 -isopentenyl adenosine (i 6 A), a novel A 3 R-selective ligand, via comprehensive modified adenosine library screening. Cryo-EM analyses of A 3 R-G i signaling complexes with two nonselective and three selective agonists revealed the structural basis for A 3 R activation. We further conducted structure-guided engineering of m 6 A-insensitive A 3 R, which would greatly facilitate future discoveries of the physiological functions of the selective activation of A 3 R by modified adenosines. Our results clarify the selective activation of adenosine receptors, providing the basis for future drug discovery.
Open AccessStructural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor
Adenosine receptors, expressed across various tissues, play pivotal roles in physiological processes and are implicated in diverse diseases, including neurological disorders and inflammation, highlighting the therapeutic potential of receptor-selective agents. The Adenosine A3 receptor (A 3 R), the last identified adenosine receptor, is also activated by breakdown products of post-transcriptionally modified tRNA and exhibits dual roles in neuron, heart, and immune cells, and is often overexpressed in tumors, making it a target for anticancer therapy. Despite extensive studies on the other adenosine receptors, the structure and activation mechanism of A 3 R, especially by selective agonists like N 6 -methyladenosine (m 6 A) and namodenoson, remained elusive. Here, we identified N 6 -isopentenyl adenosine (i 6 A), a novel A 3 R-selective ligand, via comprehensive modified adenosine library screening. Cryo-EM analyses of A 3 R-G i signaling complexes with two nonselective and three selective agonists revealed the structural basis for A 3 R activation. We further conducted structure-guided engineering of m 6 A-insensitive A 3 R, which would greatly facilitate future discoveries of the physiological functions of the selective activation of A 3 R by modified adenosines. Our results clarify the selective activation of adenosine receptors, providing the basis for future drug discovery.
- Open Access
- 7 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 693, 149361
Optimizing cryo-EM structural analysis of Gi-coupling receptors via engineered Gt and Nb35 application
- 7 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 693, 149361
Open AccessOptimizing cryo-EM structural analysis of Gi-coupling receptors via engineered Gt and Nb35 application
- Open Access
Structure and dynamics of the RF-amide QRFP receptor GPR103
Pyroglutamylated RF amide peptide (QRFP) is a type of peptide hormone with a C-terminal RF-amide motif. QRFP selectively activates class-A categorized GPCR, GPR103 to exert various physiological functions such as energy metabolism and appetite regulation. Here, we report the cryo-electron microscopy structure of the QRFP-GPR103-G q complex at 3.3 Å resolution. Unlike class-A GPCR, QRFP adopts an extended structure baring no secondary structure, with its N-terminal and C-terminal sides recognized by extracellular and transmembrane domains, respectively, of GPR103. The C-terminal heptapeptide of QRFP penetrates into the orthosteric pocket to act in receptor activation. Particularly, the residues that recognize the RF-amide are highly conserved in the RF-amide receptors. Notably, the unique N-terminal helix-loop-helix of the receptor traps the N-terminal side of QRFP with the pendulum-like motion to guide QRFP into the ligand-binding pocket. This movement, reminiscent of class B1 GPCRs except for orientation and structure of the ligand, is critical for the high affinity binding and receptor specificity of QRFP. Structural comparisons with closely related receptors, including RY-amide peptide-recognizing GPCRs, revealed conserved and diversified peptide recognition mechanisms, providing profound insights into the biological significance of RF-amide peptides. This study not only advances our understanding of GPCR-ligand interactions, but also paves the way for the development of novel therapeutics targeting metabolic and appetite disorders and emergency medical care.
Open AccessStructure and dynamics of the RF-amide QRFP receptor GPR103
Pyroglutamylated RF amide peptide (QRFP) is a type of peptide hormone with a C-terminal RF-amide motif. QRFP selectively activates class-A categorized GPCR, GPR103 to exert various physiological functions such as energy metabolism and appetite regulation. Here, we report the cryo-electron microscopy structure of the QRFP-GPR103-G q complex at 3.3 Å resolution. Unlike class-A GPCR, QRFP adopts an extended structure baring no secondary structure, with its N-terminal and C-terminal sides recognized by extracellular and transmembrane domains, respectively, of GPR103. The C-terminal heptapeptide of QRFP penetrates into the orthosteric pocket to act in receptor activation. Particularly, the residues that recognize the RF-amide are highly conserved in the RF-amide receptors. Notably, the unique N-terminal helix-loop-helix of the receptor traps the N-terminal side of QRFP with the pendulum-like motion to guide QRFP into the ligand-binding pocket. This movement, reminiscent of class B1 GPCRs except for orientation and structure of the ligand, is critical for the high affinity binding and receptor specificity of QRFP. Structural comparisons with closely related receptors, including RY-amide peptide-recognizing GPCRs, revealed conserved and diversified peptide recognition mechanisms, providing profound insights into the biological significance of RF-amide peptides. This study not only advances our understanding of GPCR-ligand interactions, but also paves the way for the development of novel therapeutics targeting metabolic and appetite disorders and emergency medical care.
- Open Access
Optimizing Cryo-EM Structural Analysis of G i -coupling Receptors via Engineered G t and Nb35 Application
Cryo-EM single particle analysis has recently facilitated the high-resolution structural determination of numerous GPCR-G complexes. Diverse methodologies have been devised with this trend, and in the case of GPCR-G i complexes, scFv16, an antibody that recognizes the intricate interface of the complex, has been mainly implemented to stabilize the complex. However, owing to their flexibility and heterogeneity, structural determinations of GPCR-G i complexes remain both challenging and resource-intensive. By employing eGα t , which exhibits binding affinity to modified nanobody Nb35, the cryo-EM structure of Rhodopsin-eGα t complex was previously reported. Using this modified G protein, we determined the structure of the ET B -eG t complex bound to the modified Nb35. The determined structure of ET B receptor was the same as the previously reported ET B -G i complex, and the resulting dataset demonstrated significantly improved anisotropy. This modified G protein will be utilized for the structural determination of other GPCR-G i complexes. Highlights: The study introduces the engineered G protein subunit eGα T , which enhances the resolution of GPCR-G protein structures by suppressing G protein conformational fluctuations and is particularly beneficial for G i -coupled receptors. The cryo-EM structure of the ET B receptor complexed with eG t -Nb35 reveals improved map quality, reduced anisotropy, and isotropic density distribution, increasing the accuracy of structural analysis. Structural comparison between ET B -G i and ET B -eG t reveals similar receptor-G protein interactions, demonstrating the utility of eG t -Nb35 for studying GPCR-G i complexes and the potential for broader applications within the G i family.
Open AccessOptimizing Cryo-EM Structural Analysis of G i -coupling Receptors via Engineered G t and Nb35 Application
Cryo-EM single particle analysis has recently facilitated the high-resolution structural determination of numerous GPCR-G complexes. Diverse methodologies have been devised with this trend, and in the case of GPCR-G i complexes, scFv16, an antibody that recognizes the intricate interface of the complex, has been mainly implemented to stabilize the complex. However, owing to their flexibility and heterogeneity, structural determinations of GPCR-G i complexes remain both challenging and resource-intensive. By employing eGα t , which exhibits binding affinity to modified nanobody Nb35, the cryo-EM structure of Rhodopsin-eGα t complex was previously reported. Using this modified G protein, we determined the structure of the ET B -eG t complex bound to the modified Nb35. The determined structure of ET B receptor was the same as the previously reported ET B -G i complex, and the resulting dataset demonstrated significantly improved anisotropy. This modified G protein will be utilized for the structural determination of other GPCR-G i complexes. Highlights: The study introduces the engineered G protein subunit eGα T , which enhances the resolution of GPCR-G protein structures by suppressing G protein conformational fluctuations and is particularly beneficial for G i -coupled receptors. The cryo-EM structure of the ET B receptor complexed with eG t -Nb35 reveals improved map quality, reduced anisotropy, and isotropic density distribution, increasing the accuracy of structural analysis. Structural comparison between ET B -G i and ET B -eG t reveals similar receptor-G protein interactions, demonstrating the utility of eG t -Nb35 for studying GPCR-G i complexes and the potential for broader applications within the G i family.